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Summary.-Sixty-two patients with Hodgkin's disease have been followed for one
year from the start of treatment. Immunological assessments were repeated after
intensive treatment, in patients relapsing and in those in remission at one year. In
patients achieving remission, overall cellular immunity, after deteriorating with
therapy, particularly cytotoxic chemotherapy, returned to pre-treatment levels in
remission when there was little evidence of cellular immune disturbance. Serum IgG
and IgM levels fell with intensive chemotherapy in splenectomized patients. IgA and
IgM levels were lower (irrespective of splenectomy or therapy status) in remission
than at presentation or after treatment. Relapse or non-response was usually associ-
ated with deteriorating cellular immunity. Herpes zoster/varicella and candida
infections (seen in 6 patients) were preceded by, or associated with, deterioration of
cellular immunity.
DISTURBANCES in immunity may be seen
in patients with generalized Hodgkin's
disease (Young et al., 1972; Hancock et al.,
1977) but little is known about the long-
term effects of the disease and its treat-
ment on immune function. We report here
the assessment of immunity in a group of
62 patients with Hodgkin's disease at
presentation and during follow-up for one
year from start of treatment; the findings
are correlated with method of treatment,
splenectomy and progress.
METHODS
P>eripheral blood lymp)hocyte counts. These
were performed at each stage of assessment.
Cellular inirnmunity
Intradermal skin tests. These w,ere per-
formed with 4 or 5 of the following recall
antigens: Candida albicans antigen 1/100
(Hollister Stiers); mumps virus antigen (Eli
Lilly); old tuberculin 1/1000; streptokinase/
streptodornase 50 units (Lederle); Tricho-
phyton antigens 1/30 (Hollister Stiers). The
skin test sites were each measured at 48 h,
and the patient considered immunocompetent
if induration of 5 mm or more in one or more
test sites was observed.
Leucocyte-migration inhibition tests.-The
leucocyte-migration inhibition test was modi-
fied from the method of Soberg and Bendixen
(1967). Separated peripheral leucocytes were
allowed to migrate from micro-capillary tubes
in wells containing (a) purified protein deriva-
tive, (b) Candida albicans extract and (c) con-
trol medium. Migration areas with antigens in
each experiment were statistically compared
with control migration areas (Student's t test)
and significant inhibition of migration was
said to have occurred if P < 0 05. If signifi-
cant migration inhibition occurred with one
or both antigens, the patient wAas considered
immunocompetent in this test.
Overall assessment of cellular immunity.-
This was obtained by combining the results of
skin and leucocvte migration tests, the patient
being, considered immunocompetent if he
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showed a normal response in either or both
tests.
Each patient was also individually assessed
in each test of cellular immunity for improve-
ment or deterioration in personal responses.
Humoral inm unity
Serum immunoglobulin levels were deter-
mined by automated immunoprecipitation
(Ritchie et al., 1973), the local standard pre-
paration being calibrated in relation to the
mass equivalent of the WTHO preparation
67/99 (Humphrey and Batty, 1974). The
normal adult ranges (g/l serum) in our labora-
tory are IgG 5-00-16-00, IgA 1-25-4.25, IgM
0*47-1-70.
Patients
Sixty-two patients with Hodgkin's disease
were assessed at presentation, immediately
following radiotherapy or before the third or
fourth course of intensive chemotherapy, and
either during relapse or after one year's
remission.
It is the policy of the Lymphoma Group in
Sheffield, U.K., to select patients for laparo-
tomy and splenectomy on the basis of clinical
staging and histological type. Those patients
wxith Stage IA-IIA disease of lymphocyte-
predominant and nodular-sclerosis histology,
and with Stage IIIB-IVA-IVB (all histo-
logical types) do not proceed to laparotomy;
all other patients do. After pathological
staging, patients with Stage I-IIIA disease
have radical radiotherapy (mantle, inverted Y
or total nodal irradiation); patients Mwith
Stage IIIB-IV disease have intensive chemo-
therapy (modified MOPP, see appendix).
Of the 62 patients, 28 patients underwrent
splenectoiny, and of these, 12 were subse-
quently treated with chemotherapy, 16 with
radiotherapy. Ten of the patients receiving
chemotherapy and 9 of those receiving radio-
therapy were in complete remission one year
after the start of treatment. Two of the
chemotherapy and 2 of the radiotherapy
group have died (only one with disseminated
disease). One ofthe chemotherapy and 4 ofthe
radiotherapy group relapsed during follow-up,
after a period ofremission. Of the 34 patients
not undergoing splenectomy, 18 had radio-
therapy and 16 had chemotherapy. Fourteen
of the radiotherapy and 5 of the chemo-
therapy group were in remission after one
year. There were no relapses and only one
death (from generalized disease) in the radio-
tlherapy group. In the chemotherapy group,
7 patients died with generalized disease with-
out achieving remission (the non-response
group) and 2 patients died ofunrelated causes.
Two patients relapsed after a period of remis-
sion. Three radiotherapy patients were lost to
long-term follow-up.
Seven patients (mean age 29-2 ± 9-3 s.e.)
were re-assessed during relapse and 38 (mean
age 37-9 + 2-8 s.e.) after one year ofremission
from the start of therapy. In the latter group
23 patients (9 of whom had had splenectomy)
Aierere-assessed 9-11 months following
radiotherapy, and 15 (10 of whom had had
splenectomy) before the eighth course of
MOPP (i.e. after a 3-month period without
chemlotherapy). In the remission group there
were 8 patients with Stage IA disease, 5 with
Stage IIA, 2 with Stage JIB, 8 with Stage
IIIA, 5 with Stage IIIB, 4 with Stage IVAand
6 with Stage IVB. Histology w%as lymphocyte-
predominant in 2, nodular-sclerosis in 11,
mixed-cell in 20 and lymphocyte-depletion in
5 cases. In the relapse group, there were 3
patients writh Stage IIA disease, 1 with Stage
IIB, 1 with Stage IIIA and 1 with Stage IVA
at presentation the histology was nodular-
sclerosis in 4 and mixed-cell in 3 cases. In the
non-response group (mean age 47-8 ± 8-7 s.e.)
there were 2 patients with Stage IIIB, 1 with
Stage IVA and 4 with Stage IVB at presenta-
tion; the histology was nodular-sclerosis in 2,
mixed-cell in 2 and lymphocyte-depletion in
3 cases.
The results in the remission, relapse and
non-response groups were recorded (Table,
where the means + s.e. are shown). To reduce
the effects ofthe variations in the basic levels
of each quantitative variable (neutrophils,
lymphocytes, immunoglobulins) between the
patients, the changes-pre-treatment minus
post-treatment on one hand, and pre-treat-
ment minus remission on the other for each
of the variables were considered. As a simple
first step, changes within the groups of
patients attaining remission, not responding
to treatment or subsequently relapsing were
analysed separately using Student's t test.
In a further analysis of the data, multiple
linear regressions Nere used in an attempt to
relate the changes for each ofthe quantitative
variables to the known factors such as his-
tology, stage, symptoms, splenectomy/no
splenectomy, remission/no remission. Little in
the way of significant explanatory effects
emerged, although this was due not so much
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to lack offit ofthe regression model, as to the
large variability in the data.
Patients in remission were then assessed, to
relate the relative changes in levels for each of
the variables to the two main factors (i.e.
radiotherapy/chemotherapyandsplenectomy/
no splenectomy). A two-way analysis of
variance with interaction with unequal
numbers of observations in the cells (Scheff6,
1960) was used. Inspection ofthe data reveal-
ed that the underlying assumption of nor-
mality seemed reasonable.
RESULTS
(a) Patients in remission, in relapse or not
responding to treatment (see Table)
In patients achieving remission, neutro-
phil and lymphocyte counts fell signifi-
cantly with treatment (both P < 0-001)
before recovering significantly in remis-
sion (P < 0-01 and < 0-001 respectively).
Serum IgG, IgA and IgM levels all fell
significantly with treatment (P < 0-05,
< 0-005 and < 0-01 respectively); the IgA
and IgM levels fell further in remission
(P < 0*05 and < 0-001 respectively).
Minimal depression ofoverall and skin-test
immunocompetence, and improvement in
immunocompetence as measured by leuco-
cyte migration inhibition were seen with
therapy; the results in remission were
similar to those at presentation.
In patients in relapse, leucocyte and
immunoglobulin levels showed similar
tendencies to those seen in the remission
group. Lymphopenia (< 1-0 x 109/1) was
seen in 4/7 patients in relapse and only 2/7
showed normal cellular immunocompe-
tence at this stage.
In assessments of patients failing to
respond to treatment, results (before and
after therapy) were generally more depres-
sed than in the othergroups. Three ofthe 7
patients in this group had normal immu-
nity at presentation; after treatment only
2 were immunocompetent.
(b) Patients attaining remission; analysis
of changes according to splenectomy and
therapy status
Leucocyte counts (Fig. 1).-The drop in
neutrophil and lymphocyte counts after
treatment was significantly larger
(P < 0-05 and < 0-01 respectively) in
non-splenectomized patients. The change
from pre-treatment to final (remission)
counts was significantly different
(P < 0-025) only for neutrophil counts,
final levels being relatively higher in
splenectomized patients.
X10/L
-2-0
-1-0
0
.1-01
+2-0
+3-01
post final
X109lL
-u-5
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Neutrophil Counts
post final
Lymphocyte Counts
FIG. 1.-Mean changes in leucocyte counts
from before treatment to following treat-
ment (post) and to remission (final) assess-
ments in groups of patients attaining
remission. Key: RT, Radiotherapy; S,
Splenectomy; CT, Chemotherapy; NS, No
splenectomy.
Immunoglobulins (Fig. 2).-Patients
having splenectomy and cytotoxic chemo-
therapy showed significantly (P < 0-01)
greater falls in IgM and IgG levels than
any ofthe othergroups aftertreatment. In
remission, serum IgM levels in splenecto-
mized chemotherapy patients remained
low, but the levels in the other groups also
fell markedly. From post-treatment to
final assessments, the change in levels in
non-splenectomized patients was signifi-
cantly greater than in splenectomized
patients (P < 0-05). The changes in IgG
levels from post-treatment to final values
were significantly different (P < 0-05)
between chemotherapy and radiotherapy
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Fic. 2. Mean changes in serum immunoglobulin levels from before treatment to following treatmenit
(post) an(d to remission (final) assessment,s in groups of patients attaining remissioni. Key: }AT,
Radiotherapy; 5, Splenectomy; CT, Chemotherapy; NS, No splenectomy.
grouips, the former grouips showing increas-
ing and the latter groups decreasing levels.
Cellular immunity. The changes in
cellular immunity between groups mir-
rored those of the remission groups as a
whole, although skin-test and overall
immunocompetence were more depressed
by chemotherapy than by radiotherapy.
Splenectomy did not obviously influence
cellular immune function after treatment
or in remission.
(c) Correlations with infection.-Infec-
tions are a recognized feature of Hodgkin's
disease, particularly patients with advanc-
ed disease and undergoing immunosup-
pressive treatment (Casazza, Duvall and
Carbone, 1966).
The cause of death in patients not
responding to treatment was invariably
bronchopneumonia. In these patients there
was marked deterioration in cellular
immunity following treatment; levels in all
immunoglobulin classes fell more than in
the other groups (Table).
Three patients in the splenectomy
group died of ftilminating septicaemia
(Hancock et al., 1976a). Pre-terminal
immune assessment showed deteriorating
cellular immnunity and inappropriately low
IgM levels.
Three patients (2 having undergone
splenectomy) developed herpes zoster
infection during the follow-up period. In
2 this was associated with deteriorating
cellular immunity and preceded clinical
relapse. In the third patient, infection
followed radical radiotherapy, when cellu-
lar immunity, previously normal, was
depressed; this patient achieved, and is still
in, remission and cellular immunity is
again normal.
Two patients (both splenectomized)
developed varicella infection, one during
total nodal irradiation and the other dur-
ing intensive chemotherapy. In both cases,
temporary depression of cellular immunity
was noted with treatment, and in one case
varicella was followed by severe oral
candidiasis; both patients achieved, and
are still in, remission with normal im-
munity.
No bizarre opportunistic infections were
seen but one totally anergic patient with
Stage IVB disease (lymphocyte-depleted
g,/L
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0
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histology) responding only partially to
chemotherapy, developed renal candidiasis
as a terminal feature.
The list of infections discussed above is
not exhaustive, as trivial non-specific
respiratory and mucosal infections were
not documented.
DISCUSSION
Variable changes in the immunological
status of patients with Hodgkin's disease
in the period following radical radio-
therapy or intensive chemotherapy have
been reported. Both radiotherapy (Gross,
Manfredi and Protos, 1973; Chee, Illberg
and Rickinson, 1974; Raben et al., 1976)
and chemotherapy (review Harris et al.,
1976) may depress immunity, but the
improvement in the patients' general
condition following remission ofthe malig-
nancy may result in normal or improved
immune function (Sokal and Primikirios,
1961; Young et al., 1972). In patients with
Hodgkin's disease studied 5 years after
completing radical radiotherapy, no gross
defects in immunity were found (Kun and
Johnson, 1975). Short intensive courses of
chemotherapy, whilst initially suppressing
humoral and cellular immunity, may be
followed by "rebound-overshoot" recovery
(Serrou, Dubois and Silva, 1974; Harris
et at., 1976) and even after prolonged
continuous chemotherapy, immunity may
be only slightly depressed or may even
recover to normal (Chang, Stutzman and
Sokal, 1975). Cessation of long-term
therapy is followed by rapid recovery
of any depression of immune function
(Borella, Green and Webster, 1972).
Such observations may indicate dif-
ferences in methods of assessment of
immunity and the variable immuno-
suppressive effects of cytotoxic drugs and
therapeutic regimes being used.
In a preliminary report (Hancock et al.,
1976b) of our follow-up results, we found
that, regardless of whether splenectomy
had been performed, overall cellular im-
munity deteriorated with intensive treat-
ment, particularly chemotherapy. Skin
reactivity deteriorated, especially in
chemotherapy patients, eventhoughleuco-
cyte migration reactivity improved mar-
ginally. Serumiminunoglobulins,andparti-
cularly IgM levels, fell during intensive
therapy in spleneetomized patients. Three
patients in the latter group died of fulmi-
nating septicaemia during or shortly after
treatment (Hancock et al., 1976a) and it
may be that IgM immunoparesis was a
contributing feature in the genesis of their
infections.
The present study confirms many of our
previous findings, but further analysis
shows that early falls in serum IgG and
IgM classes are seen with intensive chemo-
therapy in splenectomized patients.
In the present follow-up study, 6
patients (4 splenectomy, 2 non-splenec-
tomy) developed viral or fungal infections
during or following intensive treatment.
All had shown marked deterioration of
cellular immunity, and two subsequently
relapsed. No further major bacterial
infections have been seen, except in those
dying with disseminated disease, when the
terminal event was invariably broncho-
pneumonia.
One year after the start of therapy,
patients in remission showed no major
differences in cellular immunity from their
initial assessments, though individual
patients showed conversion from non-
reactivity to reactivity and vice versa.
Splenectomy or mode of therapy did not
ultimately affect the assessment of cellular
immunity in remission. At remission,
serum immunoglobulin levels were gener-
ally lower than after treatment, with
the exception that IgG levels were re-
covering in patients having maintenance
chemotherapy. The fall in IgA levels was
much less in non-splenectomized patients
having radiotherapy. It is of importance
that the early major differences in the fall
in IgM levels between the splenectomized
patients having chemotherapy and all
other groups was considerably reduced by
the time of remission.
The trends in the groups of patients not
responding to treatment or subsequently
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relapsing were similar to those attaining
remission, but there were some obvious
differences in cellular immunity. Lympho-
penia was common in patients in relapse,
and in the relapse group as a whole cellular
immunity was markedly depressed, prob-
ably as a marker ofactive disease. Cellular
immunity in these patients, and strikingly
in the non-response cases, was worse than
with the remission group at presentation
and after treatment. In the case ofthe non-
response group, these findings may be
related to the high incidence ofgeneralized
disease and lymphocyte-depleted histology
at presentation.
The relative depression of humoral
immunity expected with advanced disease
(Aisenberg and Leskowitz, 1963) was not
seen, with the exception that in the
non-response group low initial and post-
treatment serum IgG levels were demon-
strated.
It has been suggested that splenecto-
mized patients are better able to tolerate
radiotherapy (Saltzman and Kaplan, 1971)
and cytotoxic drugs (Pannetiere and
Coltman, 1973). Certainly our study
confirms a possible "protective" effect on
peripheral leucocyte counts in splenecto-
mized patients, counts in these patients
remaining higher than in those not having
splenectomy.
In conclusion it seems that regular
assessment of immune status in patients
with Hodgkin's disease may prove a
marker ofdisease activity. Relapse or non-
response seems to be associated with
deteriorating, and remission with improv-
ing, cellular immunity. The importance of
the falling immunoglobulin levels in
patients in remission at one year, and
particularly the early fall in IgM and IgG
in splenectomized patients receiving
chemotherapy, is uncertain, but the pos-
sible role of IgM immunoparesis as a
predisposing factor in the development
systemic sepsis must be carefully ass-
essed by continued observation of these
patients.
We are grateful to the consultant medi-
cal staff of Weston Park Hospital whose
patients have been studied; and to the
Cancer Research Campaign (Yorkshire
Branch) for financial assistance.
APPENDIX
Intensive cyclical chemotherapy
Modified MOPP regime
Mustine 6 mg/M2 i.V. Days 1
Vincristine (Oncovin) and 8
14 mg/m2 iV. J
Oral procarbazine IOO mg/M2 Days
Oral prednisolone 40 mg/dav f 1-14
Six courses beginning at 28-dayintervals.
Then 4 further courses at 3-monthly
intervals.
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